[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 50, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1193748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 713000, "exercisedValue": 20395892, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 735000, "exercisedValue": 8888907, "unexercisedValue": 636903}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 36.27, "open": 36.45, "dayLow": 36.0801, "dayHigh": 36.83, "regularMarketPreviousClose": 36.27, "regularMarketOpen": 36.45, "regularMarketDayLow": 36.0801, "regularMarketDayHigh": 36.83, "payoutRatio": 0.0, "beta": 0.633, "forwardPE": -24.377485, "volume": 905118, "regularMarketVolume": 905118, "averageVolume": 4692439, "averageVolume10days": 3037830, "averageDailyVolume10Day": 3037830, "bid": 36.73, "ask": 36.9, "bidSize": 6, "askSize": 6, "marketCap": 4160868096, "fiftyTwoWeekLow": 18.92, "fiftyTwoWeekHigh": 52.81, "allTimeHigh": 99.41, "allTimeLow": 0.88, "fiftyDayAverage": 33.54, "twoHundredDayAverage": 29.664425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3447052800, "profitMargins": 0.0, "floatShares": 110529198, "sharesOutstanding": 113036344, "sharesShort": 24785654, "sharesShortPriorMonth": 25450539, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.2193, "heldPercentInsiders": 0.021710001, "heldPercentInstitutions": 0.65608, "shortRatio": 5.46, "shortPercentOfFloat": 0.2628, "impliedSharesOutstanding": 113036344, "bookValue": 6.341, "priceToBook": 5.805078, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -237394000, "trailingEps": -2.12, "forwardEps": -1.51, "52WeekChange": -0.2853815, "SandP52WeekChange": 0.1326145, "quoteType": "EQUITY", "currentPrice": 36.81, "targetHighPrice": 125.0, "targetLowPrice": 36.0, "targetMeanPrice": 93.38889, "targetMedianPrice": 100.5, "recommendationMean": 1.38889, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 714569984, "totalCashPerShare": 6.322, "totalDebt": 755000, "quickRatio": 27.413, "currentRatio": 28.339, "debtToEquity": 0.106, "returnOnAssets": -0.20482, "returnOnEquity": -0.29227, "freeCashflow": -150900256, "operatingCashflow": -224576000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "postMarketChangePercent": -0.8421661, "postMarketPrice": 36.5, "postMarketChange": -0.31000137, "regularMarketChange": 0.5400009, "regularMarketDayRange": "36.0801 - 36.83", "shortName": "Viking Therapeutics, Inc.", "longName": "Viking Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1764367191, "regularMarketTime": 1764352801, "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 4692439, "fiftyTwoWeekLowChange": 17.890001, "fiftyTwoWeekLowChangePercent": 0.94556034, "fiftyTwoWeekRange": "18.92 - 52.81", "fiftyTwoWeekHighChange": -16.0, "fiftyTwoWeekHighChangePercent": -0.3029729, "fiftyTwoWeekChangePercent": -28.538149, "earningsTimestamp": 1761163200, "earningsTimestampStart": 1761163200, "earningsTimestampEnd": 1761163200, "marketState": "CLOSED", "regularMarketChangePercent": 1.4888363, "regularMarketPrice": 36.81, "earningsCallTimestampStart": 1761165000, "earningsCallTimestampEnd": 1761165000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.12, "epsForward": -1.51, "epsCurrentYear": -2.60996, "priceEpsCurrentYear": -14.103664, "fiftyDayAverageChange": 3.2700005, "fiftyDayAverageChangePercent": 0.09749554, "twoHundredDayAverageChange": 7.1455765, "twoHundredDayAverageChangePercent": 0.24088033, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]